Innate Pharma (IPHA) Debt Ratio (2017 - 2025)

Innate Pharma (IPHA) has reported Debt Ratio for 9 consecutive years, with 0.36 the latest figure, recorded in Q4 2025.

• Quarterly Debt Ratio rose 28.96% year-over-year to 0.36 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.36 (up 28.96% YoY) and the FY2025 annual result came in at 0.5, up 39.93% from the prior year.
• Debt Ratio grew to 0.36 in Q4 2025 per IPHA's latest filing, from 0.29 in the prior quarter.
• Over the last five years, Debt Ratio for IPHA reached as high as 0.36 in Q4 2025 and fell as low as 0.06 in Q2 2021.
• A 5-year average of 0.23 and a median of 0.23 in 2023 frame the typical range for Debt Ratio.
• Annual changes were most pronounced in 2022 — Debt Ratio soared 265.63% — and 2023, when it retreated 9.87%.
• Year by year, Debt Ratio stood at 0.17 in 2021, then advanced by 28.15% to 0.21 in 2022, then increased by 7.41% to 0.23 in 2023, then grew by 22.56% to 0.28 in 2024, then advanced by 28.96% to 0.36 in 2025.
• According to Business Quant data, Debt Ratio over the past three periods registered 0.36, 0.29, and 0.28 for Q4 2025, Q2 2025, and Q4 2024 respectively.